Advisory Consultant
CurrentAustralian Regenerative Medicine Institute 2020 - present* Member of Leadership Advisory Board*Chair of Industry Advisory CommitteeHeadway Animal Health (Generics Business) - 2022 - present* Manage the entry of a new generics company onto the Australian Veterinary Market with 3 existing injectable products, a new oral product (for feline dermatophytosis - under APVMA permit), and a pipeline of >20 products for a range of conditions (S2, S4 & S8).* Successful transfer of existing products onto the market with new branding & trademarks / pricing incl. distribution agreements and delivery of product.* Opened new warehouse/IT system.* Launched new product (for feline dermatophytosis) into the Australian market * 1st (and then subsequent) export shipments of product (to SE Asia).* Launced new antiparasiticides onto the AU market - focused on shelters on track for >$1m sales in year 1* Launched new nutraceutical rangeAusBiotech* Supporting a consortium project, led by AusBiotech with support from MTP Connect to build on Australia's expertise in the Regenerative Medicine Industry. The project will deliver:- a researched strategic roadmap for the RM sector's development in Australia- determine a sustainable funding and model structure for an RM sector "catalyst" collaboration body- establish annual data points and information resources- map the pathway for a typical product from early research to market and patients receiving a therapy- map the global pipeline of cell and gene therapy products on the horizon* Singapore based private stem cell company - Delivered business development financial modelling (template): used to predict risk-weighted costs/revenues and value of the company at varying stages of development, and thereby to licence their phase 1 product globally.* Large Pharma - Advised on development of a new range of specialized animal health products.
